MiMedx Group (MDXG) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Zevra Therapeutics (ZVRA) has outperformed MiMedx Group (MDXG) over the past year, gaining 5.3% versus a loss of 32.5%. Over five years, ZVRA leads with a +16.6% price change compared with -30.9% for MDXG. MiMedx Group is the larger company by market cap ($681.5 million vs $676.4 million), about 1.0 times the size.
On valuation, Zevra Therapeutics trades at a lower forward P/E (10.6x vs 23.4x for MiMedx Group).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDXG | ZVRA |
|---|---|---|
| Share price | $4.67 | $11.39 |
| Market cap | $681.51M | $676.38M |
| 1-day change | +1.08% | +3.55% |
| YTD return | -31.02% | +27.12% |
| 1-year return | -32.51% | +5.27% |
| 5-year return | -30.92% | +16.58% |
| P/E ratio (TTM) | 116.75 | 11.99 |
| Forward P/E | 23.35 | 10.58 |
| EPS (TTM) | $0.04 | $0.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.97 | $15.04 |
| 52-week low | $3.03 | $8.01 |
| Distance from 52-week high | -41.41% | -24.24% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +58.46% | +119.49% |
| Average volume | 1.23M | 1.09M |
| Shares outstanding | 145.93M | 59.38M |
| Employees | 808 | 61 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZVRA has outperformed MDXG by 37.8 percentage points over the past year.
- MiMedx Group trades at a higher earnings multiple (116.8x vs 12.0x trailing P/E).
About MiMedx Group
MDXG stock →MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
Health Care · Medical/Dental Instruments · 808 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees
MDXG vs ZVRA FAQ
Which is bigger, MiMedx Group or Zevra Therapeutics?
MiMedx Group (MDXG) is larger, with a market capitalization of $681.51M compared with $676.38M for Zevra Therapeutics (ZVRA).
Which stock has performed better over the past year, MDXG or ZVRA?
ZVRA returned +5.27% over the past 12 months, compared with -32.51% for MDXG (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, MDXG or ZVRA?
ZVRA has the lower trailing P/E at 12.0, versus 116.8 for MDXG. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are MiMedx Group and Zevra Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for MiMedx Group and Biotechnology: Pharmaceutical Preparations for Zevra Therapeutics.